Exagen Inc. (XGN)
Market Cap | 37.52M |
Revenue (ttm) | 45.56M |
Net Income (ttm) | -47.39M |
Shares Out | 16.83M |
EPS (ttm) | -2.77 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 12,793 |
Open | 2.26 |
Previous Close | 2.25 |
Day's Range | 2.16 - 2.26 |
52-Week Range | 2.04 - 9.20 |
Beta | 1.27 |
Analysts | Buy |
Price Target | 6.63 (+197.31%) |
Earnings Date | May 9, 2023 |
About XGN
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue dis... [Read more]
Financial Performance
In 2022, Exagen's revenue was $45.56 million, a decrease of -5.66% compared to the previous year's $48.30 million. Losses were -$47.39 million, 76.5% more than in 2021.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for XGN stock is "Buy." The 12-month stock price forecast is $6.63, which is an increase of 197.31% from the latest price.
News

Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
Exagen Inc. (XGN) delivered earnings and revenue surprises of 18.31% and 48.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results
Record AVISE® CTD Volume in 2022 Record AVISE® CTD Volume in 2022

Exagen Inc. to Participate in Upcoming March Conferences
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following March inve...

Exagen Inc. to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
SAN DIEGO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life ...

Exagen Inc. Elects Tina S. Nova, Ph.D.
SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair...

Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates
Exagen Inc. (XGN) delivered earnings and revenue surprises of 38.16% and 61.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022
SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2022, aft...

Exagen Announces Appointment of John Aballi as CEO
SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), announced today that the company has appointed John Aballi as CEO and President. Longtime CEO and President Ron Rocca, who took...

Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the appointment of Andrew L. Concoff M.D. FACR, CAQSM as Chi...

Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting
SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American Colle...

Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that its collaboration with Dr. Iñaki Sanz at Emory Univers...

Exagen Inc. (XGN) Reports Q2 Loss, Lags Revenue Estimates
Exagen Inc. (XGN) delivered earnings and revenue surprises of -41.82% and 25.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the launch of a prospective clinical study designed to valid...

Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference
SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 42nd Annual Growt...

Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2022, after th...

Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility
SAN DIEGO, July 05, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced new robust, real-world evidence confirming AVISE® testing enables ...

Exagen Inc. Expands Coverage with MediNcrease
SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the addition of Exagen Inc. to MediNcrease Health Plans, LLC...

Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 42nd Annual Growth Sto...

Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE® Lupus are a contracted covered ser...

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
Exagen Inc. (XGN) delivered earnings and revenue surprises of -1.69% and 2.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Medicare Administrative Contractor (MAC) Noridian has pr...

Exagen Inc. Reports First Quarter 2022 Results
Records in Ordering Healthcare Providers and Adopters, Set All-Time Record for AVISE® CTD Monthly Volume in March Records in Ordering Healthcare Providers and Adopters, Set All-Time Record for AVISE® ...

Exagen Announces Five-Week Campaign for Lupus Awareness Month
SAN DIEGO, May 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a fiv...

Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022
SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022, after ...

Exagen Inc. to Participate in Investor Summit Group's Q2 Conference
SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in Investor Summit Group's Q2 Conference,...